We herein describe the case of a 68-year-old man who developed overt diabetes mellitus following the topical administration of dexamethasone 0.1%-containing ointment over a five-month period to treat oral lichen planus. The topical dexamethasone therapy was discontinued gradually, and the patient was subsequently treated with insulin for one month without clinical signs of overt adrenal insufficiency. An oral glucose tolerance test revealed impaired glucose tolerance after the treatment. The potential for the deterioration of glucose metabolism must be considered when patients with impaired glucose tolerance are treated with relatively low doses of topical corticosteroid ointment on the oral mucosa, even for short periods.
Introduction
Iatrogenic Cushing's syndrome is common, occurring to some degree in the majority of patients receiving long-term corticosteroid therapy, and results in the loss of the normal feedback mechanism of the hypothalamic-pituitary-adrenal (HPA) axis. The development of the features of Cushing's syndrome depends on the dose, duration and potency of corticosteroids used in clinical practice. Although the whole body administration of large amounts of corticosteroids may aggravate diabetes mellitus, the development of overt diabetes mellitus due to the topical administration of corticosteroid ointment is very rare. We herein report a case of overt diabetes mellitus caused by the topical administration of a relatively low dose of dexamethasone ointment on the oral mucosa.
Case Report
A 68-year-old man was diagnosed with oral lichen planus and treated with the topical administration of dexamethasone ointment on the oral mucosa starting in June 2011. He used 5 g of dexamethasone 0.1%-containing ointment per month. His HbA1c (National Glycohemoglobin Standardization Program (NGSP)) level rose to 6.4% in August 2011, although it had previously been 6.1% in August 2010. The patient used 10 g of the dexamethasone ointment per month starting in October 2011. He developed thirst and polyuria in November 2011 and was subsequently referred to our hospital by a neighboring hospital due to a plasma glucose level of 527 mg/dL. The patient's sister also had diabetes mellitus. No changes had been observed in his body weight over the past few years, and overeating due to oral lichen planus had not been reported in recent months. He had been treated with 2.5 mg of amlodipine for hypertension at the neighboring hospital. His height was 157.7 cm, his weight was 65.3 kg, his body mass index was 26.3 kg/m 2 , his blood pressure was 110/85 mmHg, his pulse rate was 69 beats/minute and vibratory sensation in the ankle was 12 seconds on the right and 13 seconds on the left. No Cushingoid features, such as a moon face, centripetal obesity or abdominal striae, were apparent.
The laboratory findings obtained in November 2011 were as follows: fasting plasma glucose (FPG) = 279 mg/dL, HbA1c (NGSP) = 10.8%, serum C-peptide = 3.5 ng/mL, glutamic acid decarboxylase (GAD)-Ab <0.3 U/mL, adrenocorticotropic hormone (ACTH) <2.0 pg/mL and cortisol <1.0 μg/dL (Table 1) . No diabetic complications, such as diabetic retinopathy or nephropathy, were observed. The topical administration of dexamethasone ointment was discontinued gradually, and the patient was treated with insulin therapy for one month (Figure) . The ACTH level gradually recovered, and glycemic control was improved with dietary intervention (1,440 kcal/day), without the clinical signs of overt acute adrenal insufficiency. A 75-g oral glucose tolerance test showed impaired glucose tolerance in June 2012 ( Table 2 ). The homeostatic model assessment as an index of insulin resistance (HOMA-IR) was 3.21, which confirmed the presence of insulin resistance. Remission of oral lichen planus was noted, even though the topical administration of dexamethasone ointment had been discontinued. Glycemic control was maintained with diet therapy (FPG: 95 mg/dL and HbA1c (NGSP): 5.6% in October 2013).
Discussion
The critical odds ratio (95% confidence intervals (CI)) of diabetes mellitus due to the long-term topical administration of corticosteroids has been previously reported to be 1.32 (1.14-1.54) (1) . The rate of absorption of percutaneously administered dexamethasone has been shown to be extremely low, with an average of 0.25% over eight hours (2) . However, most studies regarding the effects of corticosteroid ointment have been performed in healthy subjects; therefore, the rate of absorption of corticosteroid ointment may be higher in patients with skin disorders than in healthy subjects. The rate of absorption of corticosteroid ointment intraorally administered on the mucosa has not yet been determined. However, previous studies have reported the development of iatrogenic Cushing's syndrome due to the intranasal administration of dexamethasone (3, 4) . The rate of absorption of corticosteroid ointment intraorally administered on the mucosa may be superior to that administered percutaneously.
Based on his clinical course, the patient was diagnosed with diabetes mellitus caused by the topical administration of dexamethasone ointment on the oral mucosa. He used 5-10 mg of dexamethasone per month; therefore, 0.17-0.3 mg per day of dexamethasone topically administered on the oral mucosa completely suppressed his ACTH level and aggravated his glycemic control. The patient received a relatively low dose of dexamethasone ointment over a short period of time. He did not exhibit Cushingoid features on admission and did not present with any clinical signs of overt acute adrenal insufficiency after the dexamethasone ointment was discontinued. Impaired glucose tolerance was noted, as confirmed on a glucose tolerance test performed after the treatment. In this case, the presence of insulin resistance may have contributed to the development of overt diabetes mellitus induced by the corticosteroid ointment. The potential for the deterioration of glucose metabolism must be considered when patients with impaired glucose tolerance are treated with relatively low doses of topical corticosteroid ointment on the oral mucosa, even for short periods.
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